Skip to main content
. 2018 Sep 10;2018(9):CD007287. doi: 10.1002/14651858.CD007287.pub4

MacLean 1996.

Methods Uncontrolled phase II study
Participants 34 women with ovarian cancer and evaluable residual or recurrent disease
Interventions Subcutaneous KLH conjugate (Sialyl‐Tn)
Adjuvant: Detox B
Outcomes Survival (trial entry to death)
Immune response: humoral
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) High risk Uncontrolled trial
Allocation concealment (selection bias) High risk Uncontrolled trial
Blinding of participants and personnel (performance bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias) Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias Unclear risk Information insufficient to permit judgement of ‘low risk’ or ‘high risk’